N ITS EARLY STAGES, chronic lymphocytic leukemia (CLL) is an indolent disease, one in which malignant cells accumulate through lengthened life span rather than accelerated proliferation. This may be largely caused by increased expression of the bcl-2 gene product' or by production of interferon y (IFNy) by the malignant B cells' and resultant inhibition of apoptosis. In the later stages of CLL, which are characterized by significant anemia andor thrombocytopenia, prognosis worsens and median survival is less than two years.3 This disease is difficult to treat effectively because of the very low rate of cellular proliferation, and cures are virtually unknown. The idea was proposed long ago that if CLL cells could be induced to cycle transiently, ie, without undergoing permanent transformation, the disease would be amenable to treatment with intent to cure by using cycle-active cytotoxic drugs. A number of agents have been tested in this regard, with varying degrees of success in vitro: bacterial endotoxin, anti-p antibodies with and without phytohemagglutinin (PHA)-conditioned medium, Staphylococcus uureus protein A from Cowan I (SAC), thioredoxin, phorbol and a number of cytokines individually and in combination. Endotoxin and phorbol esters per se cannot be used in humans. Anti-p antibodies would likely affect normal as well as malignant B cells; this is complicated further because B-CLL cells express sIg at very low density.
Stimulation by cytokines appears to require an initiation signal such as anti-p antibodies, SAC, or 12-0-tetradecanoylphorbol-13-acetate (TPA).
Loxoribine and its analogues are well-characterized pleiotropic agonists of immune responses in a variety of species, including man."." The present studies were undertaken to investigate the capacity of loxoribine to induce cell-cycle entry by B-CLL cells, and the effects of any such action on cellular sensitivity to cycle-active cytotoxic drugs.
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MATERIALS AND METHODS
Cell preparation.
Human peripheral blood mononuclear cells (PBMC) from patients with CLL or hairy cell leukemia (HCL) were prepared from heparinized or citrated venous blood by ficoli-diatrizoate density gradient centrifugation. Viability, determined by tqpan blue dye exclusion, was 295%.
Lymphocyte culture. The tissue-culture medium used in these experiments, containing 10% heat-inactivated autologous plasma in an RPM-1640-based medium was prepared as described previously,lZ but without interleukin-2 (L-2) supplementation. B-CLL cells enjoyed prolonged viability in this medium. In our experience, use of fetal calf serum was significantly inhibitory. Cultures were incubated for 72 hours unless otherwise indicated.
Loxoribine. Loxoribine was synthesized and generously pro- Cell proliferation assay. PBMC from leukemic subjects were incubated in 96-well microculture plates. One hundred microliters of PBMC at 106/mL was plated in replicates of five and incubated with culture medium as a control or with incremental quantities of loxoribine as indicated. All cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 in air. Cultures were pulsed with 0.6 pCi ['HITdR (ICN Pharmaceuticals, Costa Mesa, CA) for the final 24 hours of the 72-hour culture period. Cells were harvested on a multi-sample automated harvester; ['HITdR uptake was measured by liquid scintillation spectrometry.
Histopathology and immunohistochemistry. PBMCs from leukemia patients were cultured with medium (control) or with loxoribine as described above. After 2 to 3 days' incubation, 50 pL of cultured cell suspension was transferred to microscopic slides with a cytocentrifuge. Slides were then stained with Wright-Giemsa stain according to manufacturer's recommendation (Hema-Tek, Miles Inc, Elkhart, IN).
Immunohistochemistry using antibody against K-light chain was performed on cytocentrifuged microscopic slides prepared with 50 p L of cultured cell suspension. The prepared slides were fixed in cold acetone and incubated with rabbit polyctonal antibody against &light chain13 as described. Detection of primary antibody was accomplished with horseradish peroxidase-conjugated antirabbit Ig and DAB as substrate. Tartrate inhibition of acid phosphatase activity was assessed in cytocentrifuged preparations using commercially available test kits (Sigma Chemical CO, St Louis, MO), without modification of the manufacturer's instructions.
Immunophenotyping. PBMC from leukemic patients were cultured with medium (control) or with incremental concentrations of loxoribine as shown. Thirty-six replicate wells for each culture condition were plated. After incubation, pooled cells from triplicate wells were incubated with 150 pL of antibody cocktail (Table 1) for 30 minutes, washed twice in phosphate-buffered saline (PBS) containing 2% heat-inactivated newborn calf serum and 0.2% so- dium azide (PBS-NCS) and finally resuspended in 0.5 mL PBS-NCS for flow-cytometric analysis.
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DNA content analysis. Pooled cells from triplicate wells were resuspended in 0.5 mL PBS containing 20 pg/mL propidium iodide (Sigma) and analyzed by flow cytometry.
Flow cyfometry. Analysis was performed on a FACScan (Becton Dickinson, Mountain View, CA). For immunophenotyping, light-scatter gating was used to eliminate dead cells and clumps. For each antibody tested, 30,000-count histograms of fluorescence intensity versus cell number were generated for the light-scattergated populations. For DNA content analysis, 10,000-count histograms were generated after doublet discrimination. Off-line data analysis of immunophenotyping and DNA content was performed using WinList and ModFit (Verity Software House, Topsham, MA), respectively.
RESULTS
PBMC from patients with either of two B-cell chronic leukemias (13 patients with CLL, 6 patients with HCL) were cultured with incremental concentrations of loxoribine in an attempt to induce cell-cycle entry. An unexpected selectivity of the substituted nucleoside for B-CLL cells was observed, with striking increases in DNA synthesis occurring in about three fourths (10 of 13) of B-CLL patients tested (Fig 1A) . Leukemic B cells from patients with HCL, in contrast, failed to generate meaningful proliferative responses to loxoribine (Fig 1B) . The clinical characteristics of the CLL patients studied are shown in Table 2 . Flow cytometry showed that 294% of cells from all patients were CD5", except for patient number 4 (85%) and patient number 9 (92%). Lack of correlation was found between stimulation index and absolute lymphocyte count ( r = .174), Rai stage ( r = .448), or time from diagnosis ( r = .253). PB lymphocytes from normal donors have been reported to lack proliferative responsiveness to 10xoribine.l~ Uptake of [3H]TdR was assessed after 72-hour incubation. Kinetic studies showed this to be the time of peak stimulation (Fig 2) . These latter studies also showed that the cells did not become irreversibly transformed, undergoing cycle upon cycle of mitosis; rather, [3H]TdR uptake subsided to baseline after a single peak of stimulation, despite the continued presence of the nucleoside in culture.
Morphologic confirmation of leukemic cell activation and GOODMAN ET AL cell-cycle entry was obtained by examination of cytocentrifuge preparations of cultured cells. The morphologic appearance of unstimulated, cultured B-CLL cells is shown in Fig  3A. Upon Wright-Giemsa staining, these cells manifest cytologic features typical of B-CLL, including small size, scant amounts of amphophilic cytoplasm, and relatively uniform
: Fig  3B) . Occasional mitotic figures are also seen (Fig 4) . The activated lymphocytes morphologically resemble prolymphocytes in many respects.
Parallel cultures were stained for tartrate-resistant acid phosphatase activity (TRAP), in consideration of the partial HCL-like morphologic and histochemical conversion that B-CLL cells are described to undergo upon exposure to phorbol esters.' No induction of TRAP activity (red punctate staining) and no morphologic changes suggestive of HCL are noted when comparing unstimulated (Fig 3C) with activated ( Fig 3D) cells. Positive controls were included with all TRAP stains. Nucleolar size changes are particularly striking with this stain.
Loxoribine and its analogues are well-characterized inducers of both proliferation and functional differentiation to Ig secretion in murine B cells in ~itro.'~"' Immunohistochemical stains for cytoplasmic Ig were performed, to determine if loxoribine also induced Ig production in B-CLL cells. Comparison of anti-rc staining of loxoribine-activated B-CLL cells (Fig 3F) with identically-stained unstimulated control cells (Fig 3E) clearly indicates that the loxoribinetreated cells exhibit increased cytoplasmic staining for Klight chain.
The effects of loxoribine-dependent B-CLL cell activation on cell surface antigen expression were explored. B-CLL cells were cultured with incremental concentrations of loxoribine for 72 hours, reacted with monoclonal antibodies specific for an array of surface determinants, and analyzed by flow cytometry. The data indicate that dramatic upregulation of CD22, CD23, CD25, CD38, and CD54 expression occurred, although with differing dose optima (Fig 5, upper  panels) . Interestingly, a very high proportion of cells expressed these antigens at low levels without stimulation, except for CD38, whose intermediate level expression increased to involve the great majority of cells upon activation. Marginally increased expression of CD1 IC and surface A-light chain was noted, with no significant change in CD5, HLA-DR, or CD20 staining intensity (Fig 5, lower panels) . A modest increment in the proportion of cells expressing CD20 (increasing from 5% to 35%) was observed. These findings were representative of all four patients for whom cell surface phenotypes were studied. Flow-cytometric analysis of cells from the patient of and 11% of loxoribine-stimulated cells were in S The success of a therapeutic regimen that first induces entry of malignant cells into the cell cycle and subsequently enlists cycle-active cytotoxic drugs to kill them, will depend upon the ability of cells from such patients to respond to stimulation after repeated rounds of cytotoxic therapy. Therefore, cells from a patient undergoing treatment for CLL with 2-chloro-2'-deoxyadenosine (2CdA) were obtained before initiation of treatment, and after each of his cycles of 2CdA. After one and two cycles of 2CdA (sufficient to lower the patient's peripheral white blood cell W C ] count from 94 X 109L to 10 X 109L) the patient's cells retained excellent stimulability by loxoribine in vitro relative to his initial pattern of responsiveness (Fig 6) .
In other studies, B-CLL cells were cultured with loxori-
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bine for two days to allow cells to achieve optimal degrees of sensitization before addition of various cytotoxic drugs. Three weeks thereafter, the number of viable cells per milliliter was determined. The cell count remained significantly elevated in loxoribine-activated cultures, as compared with control cultures. Dexamethasone, a noncycle active agent, failed to decrease the number of viable cells relative to control, although it did counter loxoribine-dependent proliferation (Fig 7A) . In contrast, doxorubicin and W-16, both cycle-active cytotoxic agents, exhibited synergistic killing of CLL cells, despite the fact that neither one alone induced significant cytotoxicity in the absence of loxoribine. The ability of loxoribine to sensitize CLL cells from six other patients to a variety of antileukemia drugs is shown in Fig 7B. 
DISCUSSION
In B-CLL, the malignant B cell clone has been thought to be developmentally arrested at a stage of differentiation between pre-B-cell and mature-B-cell The relative chemoinsensitivity and incurability of this disease is attributable largely to the fact that these cells are primarily small, resting Go-or GdG1,-phase cells that rarely divide and only gradually accumulate. Clinically, this is reflected in the indolent nature of a disease characterized by a long latent period. Stimulation of B-CLL cells in vivo to a state of active proliferation by a pharmacologic Loxoribine is a member of the 7,8-disubstituted guanine ribonucleoside family whose immunostimulatory capabilities have been extensively studied in vitro and in vivo.103'922-u( The data in the current communication show that loxoribine activates B-CLL cells to enter the ceil cycle and undergo proliferation. This is reflected by (1) a marked increase in r3H]TdR uptake, ( 2 ) morphologic transformation to large prolymphocytoid cells, (3) increased expression of surface activation antigens, and (4) an increased fraction of the B-CLL cell population passing through S + G2/M at the time of peak stimulation. Induction of this activated state appears to be a reversible event. Thus, if cultures are assayed after 4, 5, 6, or more days of incubation, continuing [3H]TdR uptake and proliferation do not occur. This pattern contrasts diametrically with that manifested by transformed cell lines, in which r3H]TdR uptake increases directly as a function of time, until cell crowding or exhaustion of nutrients limits the process. Thus, the possibility that loxoribine might alter the course of the disease, irreversibly transforming B-CLL cells to a more aggressive variant in vitro (ie, prolymphocytic leukemia) appears unlikely. Other studies showed that B-CLL cells retain their capacity for stimulation by loxoribine even after several cycles of antileukemic chemotherapy. In this case, the patient was treated with l-day infusional2-chlorodeoxyadenosine at 0.1 mg/kg/d, a regimen that resulted in reduction of markedly elevated pretreatment lymphocyte counts to normal levels after two cycles of therapy. These data suggest that patients could be treated with successive cycles of loxoribine, each followed by treatment with cycle-active cytotoxic agents (such as Ara-C, doxorubicin, vincristine, or etoposide either singly or in drug combinations that act at different points of the cycle), to kill cells traversing the cell cycle. Perhaps by alternating these cycles with therapy designed to attack noncycling cells, the length of time required to achieve CR may be substantially reduced, the number of patients entering CRs instead of PRs can be increased, and the duration of CRs lengthened. This strategy would enable the clinician to enlist a battery of cytotoxic drugs against B-CLL that is otherwise rarely used. An additional potential application of this observation is the sequential incubation of bone marrow (BM) cells from B-CLL patients with loxoribine and cycle-specific chemotherapeutic agents as a purging technique for autologous BM transplantation.
Experimental evidence supporting the reduction of this strategy to practice is provided by studies in which B-CLL cells were stimulated with loxoribine for 48 hours before the introduction of cytotoxic drugs into culture. Stimulated (but not control) B-CLL cells exhibited synergistic sensitivity to cycle-active cytotoxic drugs in vitro. This result contrasts starkly with the poor cytotoxic responses produced by antileukemic drugs when B-CLL cells are cultured in the absence of loxoribine, a reflection of the ineffectiveness of cycle-specific drugs on lymphocytes in Go or GdGl,.
The concentrations of loxoribine required to induce B-CLL cell activation and transformation in vitro are likely to be higher than those that will be necessary in vivo. For example, enhancement of human antibody responses to nominal antigen requires the same loxoribine concentrations in vitro as were used in the present studies.I2 However, preliminary clinical evidence for in vivo enhancement of antibody responses has been observed in a phase UII clinical trial in patients with chronic renal failure at doses as low as 0.75 mg loxoribinekg body weight, with no toxic effects noted. In fact, preclinical studies have shown preferential accumulation of loxoribine in lymph and lymphoid tissue in vivo. Thus, it is probable that the drug is concentrated in lymphoid cells and that high local concentrations may well induce activity in patients with B-CLL.
A diverse array of B-cell agonists has been evaluated in the past to determine if these cells are in fact "frozen" at a discrete stage of lymphoid differentiation, and to identify an agent that might prove to be a clinically useful B-CLL cell stimulant. Initial attempts to activate B-CLL cells were largely unsuccessful .25 However, In 1974, Fu et a1 induced
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DNA synthesis and differentiation in B-CLL cells from a patient with an IgM paraprotein, using pokeweed mitogen (PWM) with allogeneic T cells. Low-level responses were induced by other investigators using anti-p antibodies, SAC, calcium ionophore, PHA, purified protein derivative of tuberculin (PPD), PWM, Epstein-Barr virus, lipopolysaccharide, and dextran sulfate.4."* In 1980, Totterman et a126 found that phorbol ester induced over 50% of B-CLL clones to undergo differentiation. Subsequently, it has been shown that the cells of a responsive clone will move from G, to G , upon TPA, anti-p, or SAC stimulation; further progression into the cell cycle requires additional signals, as from thioredoxin, or from cytokines such as IL-2, IL-4, tumor necrosis factor a (TNFa), or low M, B-cell growth factor (BCGF).8,9,27,28 Treatment of B-CLL cells with phorbol esters such as TPA has been shown to induce cell-surface receptors for low M, BCGF.* Only IgD+IgM+ B-CLL cells were found to proliferate to BCGF alone; the combination of TPA with BCGF induced strong proliferative responses in four of six patients. These authors felt that expression of surface IgD on B-CLL cells reflected the existence of a state of "proliferation competence." However, different investigators observe that TPA results in down-regulation of surface IgD, CD20, and B2 antigen, with upregulation of IgM secretion and B7 expression."
Studies in normal murine splenocytes have shown that mRNA andor translation products for a number of cytokines (IL-l, IL-6, TNFa, IFNaIP, IFNy) are induced by loxori-
The first of these can be elicited from adherent cells and monocytoid cell lines; otherwise, the cells of origin are unknown. The ability of loxoribine to evoke cytokine secretion from normal and malignant human B cells has not yet been explored. However, it has been found that B-CLL cells secrete all of the above products except IFNa/P.2~"-33 Roles have been proposed for TNFa, IL-1, and IL-6 as autocrine growth stimuli for B-CLL cells, and for IFNy as an agent that inhibits apoptotic cell death.2 It is not unlikely that loxoribine provides (1) an initiation signal for B-CLL cell cycle entry, and (2) a stimulus for secretion of some or all of the above cytokines that promote progression through the cell cycle. Perhaps the explanation for the variability in response level of B-CLL cells from different patients lies in variability of the quantity or array of cytokines secreted in response to loxoribine. The nucleoside's capacity to synergize with cytotoxic drugs in cell killing may therefore relate not only to induction of B-CLL proliferation, but also to induction of cytokine secretion from nonleukemic cells in culture.
Evidence to date suggests that activation of B-CLL cells by loxoribine uses a pathway distinct from that used by phorbol esters. Thus, phorbol esters induce increased cell surface expression of CD5 and class I1 MHC antigens; loxoribine has no effect on the former and only a sporadic effect on the latter. Phorbols down-regulate CD20, CD21, sIgM, and sIgD; loxoribine induces none of these effects. Whereas TPA has been found to induce TRAP positivity in B-CLL cells, loxoribine fails to do so. Phorbols initiate translocation and activation of cytosolic protein bine,30.30a
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From The implications of these observations in the therapeutic armamentarium of the chronic low-grade lymphoid neoplasms are clear-the potential for inducing malignant lymphocytes into sensitive phases of the cell cycle overcomes a form of resistance to therapy, may reversibly transform a low-grade lymphocytic malignancy to a higher grade, and may thereby add significantly to the development of curative strategies for these incurable chronic neoplastic conditions. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From
